PCM
ORMP icon

Prelude Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

Prelude Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Buy
35,313
+13,700
+63% +$46.5K 0.01% 1016
2025
Q4 		$61.6K Buy
+21,613
New +$55.7K ﹤0.01% 1226
2025
Q2 		– Sell
-13,435
Closed -$28.8K – 1261
2025
Q1 		$28.8K Sell
13,435
-300
-2% -$692 ﹤0.01% 1120
2024
Q4 		$33.2K Sell
13,735
-700
-5% -$1.66K ﹤0.01% 1163
2024
Q3 		$35.2K Buy
+14,435
New +$35.2K ﹤0.01% 1227

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.37B AUM
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Prelude Capital Management's ORMP Position: Q1 2026 in Review

Prelude Capital Management increased its Oramed Pharmaceuticals (ORMP) stake by 63% in Q1 2026, buying an estimated $46.5K and bringing the position to 35,313 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #1016.

Prelude Capital Management first reported a position in ORMP in Q3 2024 and has held it in 5 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Prelude Capital Management held 35,313 shares of Oramed Pharmaceuticals worth $120K as of Q1 2026.
  • Prelude Capital Management bought 13,700 Oramed Pharmaceuticals shares in Q1 2026, an estimated $46.5K.
  • Oramed Pharmaceuticals made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1016 holding.
  • Prelude Capital Management first reported a position in Oramed Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.